{"id":"human-insulin-30-70","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This biphasic insulin formulation combines rapid-acting insulin (30%) to address postprandial (after-meal) glucose spikes with intermediate-acting insulin (70%) to provide basal glucose control throughout the day. The combination mimics the physiological pattern of endogenous insulin secretion, allowing for once or twice-daily dosing in patients with type 1 and type 2 diabetes who require insulin therapy.","oneSentence":"Human insulin 30/70 is a fixed-ratio combination of 30% short-acting insulin and 70% intermediate-acting insulin that replaces endogenous insulin to regulate blood glucose by promoting cellular glucose uptake and storage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:52.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07485101","phase":"NA","title":"Glycemic Targets During CPB in Elderly Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-04-01","conditions":"Glycemic Management During CPB in Elderly Diabetic Cardiac Surgery","enrollment":3000},{"nctId":"NCT03624062","phase":"PHASE1","title":"MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-08-31","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT07403604","phase":"PHASE1","title":"Effect of Insulin Lowering on Lipogenesis","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-04","conditions":"Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease","enrollment":25},{"nctId":"NCT06090864","phase":"PHASE1, PHASE2","title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-04-25","conditions":"Hodgkin Lymphoma, Relapse, Refractory","enrollment":31},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT05614089","phase":"PHASE4","title":"Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","status":"COMPLETED","sponsor":"Jing Luo","startDate":"2023-03-15","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes","enrollment":400},{"nctId":"NCT06968286","phase":"NA","title":"The Effect of Locally Dilvered Ciprofloxacine Loaded Injectable Platelet-rich Fibrin as an Adjunct to Non-surgical Periodontal Therapy on the Gingival Crevicular Level of Interleukin 6","status":"COMPLETED","sponsor":"Suez Canal University","startDate":"2025-01-01","conditions":"Periodontitis Stage II","enrollment":60},{"nctId":"NCT04088981","phase":"NA","title":"Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Physicians Committee for Responsible Medicine","startDate":"2025-07","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT06876207","phase":"","title":"Real-world Study on the Effectiveness and Safety of Control-IQ Technology in Teenagers With Type 1 Diabetes Engaging in Regular Physical Activity","status":"RECRUITING","sponsor":"Bruno Bombaci","startDate":"2025-06-01","conditions":"Type 1 Diabetes Mellitus","enrollment":50},{"nctId":"NCT06668714","phase":"NA","title":"Does Co-administration of Lactate Affect Postprandial Nutrient Absorption and Fat Disposition?","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-08-22","conditions":"Pre Diabetes, Metabolic Syndrome","enrollment":25},{"nctId":"NCT06925334","phase":"PHASE4","title":"A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-05-20","conditions":"Type 2 Diabetic Patients","enrollment":170},{"nctId":"NCT06911879","phase":"NA","title":"The Effect of Ketogenic-caloric Restricted Diet on Metabolic Endotoxemia in Prediabetic Obese Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Jordan","startDate":"2025-04-05","conditions":"Insulin Resistance, Metabolic Endotoxemia, Inflammation Biomarkers","enrollment":90},{"nctId":"NCT06856720","phase":"NA","title":"Impact of NMES, Aerobic, and Resistance Exercise on Glycemic Control in Older Adults With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Carlos Tavares","startDate":"2025-05-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":105},{"nctId":"NCT06656377","phase":"NA","title":"Optimization of Exercise Protocol for Prediabetic Population in Postprandial State","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2022-09-15","conditions":"Prediabetes, Exercise, Blood Glucose Profile","enrollment":25},{"nctId":"NCT06601660","phase":"NA","title":"Metabolic Investigation, Physical Performance, Physical Training At Different Times of the Day in Obese Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of Minas Gerais","startDate":"2024-09-16","conditions":"Obesity Type I and II, Obesity and Overweight","enrollment":60},{"nctId":"NCT05017675","phase":"NA","title":"Effect of Dietary SFA and Fructose on Hepatic Insulin Sensitivity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2021-11-08","conditions":"Insulin Resistance","enrollment":20},{"nctId":"NCT04791787","phase":"NA","title":"Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2020-11-25","conditions":"Glucose Metabolism Disorders (Including Diabetes Mellitus), Energy Supply; Deficiency, Type 2 Diabetes","enrollment":35},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT00671008","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT00101751","phase":"PHASE4","title":"INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":4877},{"nctId":"NCT01486862","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00476437","phase":"PHASE3","title":"Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":81},{"nctId":"NCT01308437","phase":"PHASE3","title":"Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics","status":"TERMINATED","sponsor":"Wockhardt","startDate":"2011-03","conditions":"Type I Diabetes","enrollment":134},{"nctId":"NCT00858273","phase":"NA","title":"Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2008-03","conditions":"Diabetes Mellitus, Type 1","enrollment":41},{"nctId":"NCT05095259","phase":"NA","title":"Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes","status":"UNKNOWN","sponsor":"Nordsjaellands Hospital","startDate":"2019-12-16","conditions":"Type1diabetes","enrollment":60},{"nctId":"NCT05558488","phase":"NA","title":"The Effect of a Meatless,Keto Restrictive Diet on Body Composition,Strength Capacity,Oxidative Stress,Immune Response","status":"COMPLETED","sponsor":"Katarzyna Siedzik","startDate":"2019-10-01","conditions":"Body Weight, Oxidative Stress, Trimethylamine N-oxide","enrollment":14},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT03916601","phase":"PHASE1","title":"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-13","conditions":"Type 1 Diabetes","enrollment":52},{"nctId":"NCT03384719","phase":"NA","title":"The Effect of Milk Protein vs Blends of Milk and Plant Protein on Growth Markers in 7-8 Year Old Healthy Danish Children","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2018-01-18","conditions":"Growth Acceleration, Growth; Stunting, Nutritional","enrollment":129},{"nctId":"NCT01293396","phase":"PHASE4","title":"Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT01484457","phase":"EARLY_PHASE1","title":"Controlled Insulin Delivery: Combining Technology With Treatment","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 1","enrollment":19},{"nctId":"NCT04726657","phase":"NA","title":"Comparison of Two Biphasic Insulin Regimens","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2016-01-18","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT04392882","phase":"NA","title":"Effects of Legumes Consumption on Weight Reduction","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-03-01","conditions":"Obese","enrollment":400},{"nctId":"NCT04635202","phase":"NA","title":"Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-09-09","conditions":"Metabolic Syndrome","enrollment":60},{"nctId":"NCT03994276","phase":"NA","title":"The Postprandial Effects of Chick-Pea Consumption on Glucose, Insulin, and Gut Hormone Responses (PEA-POD).","status":"COMPLETED","sponsor":"King's College London","startDate":"2019-06-25","conditions":"Postprandial Period","enrollment":29},{"nctId":"NCT04498884","phase":"NA","title":"Comparative Study of the Pharmacokinetics of Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-07-18","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT03862690","phase":"","title":"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT04226105","phase":"PHASE3","title":"Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Geropharm","startDate":"2020-01-20","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":264},{"nctId":"NCT02678390","phase":"NA","title":"Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2015-09","conditions":"Prediabetic State","enrollment":20},{"nctId":"NCT00821795","phase":"PHASE4","title":"Veterans Inpatient Insulin Study and Transition to Outpatient Therapy","status":"COMPLETED","sponsor":"Dennis G. Karounos, M.D.","startDate":"2009-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT02660242","phase":"PHASE2","title":"The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 1","enrollment":16},{"nctId":"NCT04022291","phase":"PHASE1","title":"Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2019-06-15","conditions":"Healthy Volunteer","enrollment":78},{"nctId":"NCT04184492","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-04-15","conditions":"Clamp Study","enrollment":34},{"nctId":"NCT01474018","phase":"PHASE4","title":"QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT02987751","phase":"PHASE4","title":"A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2016-12-29","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT03087721","phase":"NA","title":"High-intensity Interval, Low Volume Training in Metabolic Syndrome","status":"COMPLETED","sponsor":"Universidad de Antioquia","startDate":"2017-03-01","conditions":"Metabolic Syndrome, Insulin Resistance","enrollment":60},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT02582242","phase":"PHASE4","title":"Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-19","conditions":"Diabetes, Type 2 Diabetes Mellitus","enrollment":437},{"nctId":"NCT02762578","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":543},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT01855243","phase":"NA","title":"Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM","status":"COMPLETED","sponsor":"Cairo University","startDate":"2010-03","conditions":"Diabetes Mellitus (DM)","enrollment":63},{"nctId":"NCT01059812","phase":"PHASE3","title":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":424},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT02449603","phase":"PHASE4","title":"Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT03612778","phase":"NA","title":"Modification of Diet in Renal Transplantation (MDRT)","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2018-11-15","conditions":"Kidney Transplant; Complications","enrollment":86},{"nctId":"NCT02648217","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-01-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":263},{"nctId":"NCT03374774","phase":"","title":"A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":516},{"nctId":"NCT00659282","phase":"","title":"Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-09-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":57610},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT03333525","phase":"NA","title":"Does Protein and Fat Content of Meal Increase Glucose Concentrations","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2013-09-10","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01538511","phase":"PHASE1","title":"Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT02568384","phase":"NA","title":"Evaluation of an Ascensia Blood Glucose Meter and App System","status":"COMPLETED","sponsor":"Ascensia Diabetes Care","startDate":"2015-10","conditions":"Diabetes Mellitus","enrollment":45},{"nctId":"NCT00766298","phase":"NA","title":"Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2004-06","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT01589653","phase":"PHASE4","title":"Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":155},{"nctId":"NCT03106870","phase":"NA","title":"Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2016-06","conditions":"Gestational Diabetes Mellitus in Pregnancy","enrollment":62},{"nctId":"NCT00613951","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":182},{"nctId":"NCT01971047","phase":"PHASE4","title":"Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2013-10","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":""},{"nctId":"NCT00184600","phase":"PHASE3","title":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00564668","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":126},{"nctId":"NCT01467401","phase":"PHASE4","title":"Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT01523041","phase":"PHASE1","title":"Comparison of Two Formulations of Biphasic Insulin Aspart 70","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-11-03","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01704378","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04-18","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00184626","phase":"PHASE4","title":"Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":97},{"nctId":"NCT01527539","phase":"PHASE3","title":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-11-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT00617565","phase":"PHASE3","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-07-08","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":219},{"nctId":"NCT01519674","phase":"PHASE4","title":"Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT01527565","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-01-20","conditions":"Diabetes, Healthy","enrollment":30},{"nctId":"NCT01536626","phase":"","title":"Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":211},{"nctId":"NCT00592969","phase":"PHASE4","title":"Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":164},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT01697631","phase":"PHASE4","title":"Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-07-22","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":131},{"nctId":"NCT00791895","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-06-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":102},{"nctId":"NCT01618214","phase":"PHASE4","title":"Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01123980","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT01486381","phase":"PHASE3","title":"Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-03-20","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT01467375","phase":"PHASE3","title":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-01-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00469092","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01174303","phase":"PHASE1","title":"A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01051102","phase":"PHASE1","title":"Effect of NN5401 in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":21},{"nctId":"NCT00993096","phase":"PHASE1","title":"Investigation of the Response Relationship of NN5401 in Type 1 Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT00842361","phase":"PHASE2","title":"Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT01542424","phase":"","title":"An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-03","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1889},{"nctId":"NCT00869908","phase":"","title":"Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66726},{"nctId":"NCT01068652","phase":"PHASE4","title":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":403},{"nctId":"NCT03018665","phase":"PHASE4","title":"A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-02","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT00097877","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":293},{"nctId":"NCT00775736","phase":"","title":"Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":611},{"nctId":"NCT00605111","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":193},{"nctId":"NCT00097279","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":230}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CARDIAC ARREST"},{"count":1,"reaction":"RENAL IMPAIRMENT"}],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Human insulin 70/30 (in the United States)"],"phase":"marketed","status":"active","brandName":"Human insulin 30/70","genericName":"Human insulin 30/70","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Human insulin 30/70, also known as biphasic insulin aspart 30, is used to treat conditions such as Type 2 Diabetes Mellitus, Type 1 Diabetes, and Metabolic Syndrome. It is administered to patients with diabetes as part of their treatment regimen, often following short-term intensive insulin therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}